OPA3 Supports Pancreatic Tumor Growth Through Context-Dependent Metabolic and Hypoxic Adaptation

Authors

DOI:

https://doi.org/10.66505/cbtt.v1i4.72

Keywords:

OPA3, pancreatic cancer, mitochondrial metabolism, tumor hypoxia, HIF-1α, KRAS, tumor microenvironment

Abstract

Background: Optic atrophy protein 3 (OPA3) regulates mitochondrial function, but its contribution to cancer progression and adaptation to hypoxic tumor microenvironments remains incompletely understood.

Methods: We examined OPA3 expression across 31 cancer types and investigated its function using CRISPR/Cas9 knockout in five cancer cell lines with different KRAS backgrounds. Proliferation, clonogenic growth, mitochondrial metabolism, and ATP production were evaluated in vitro. Pancreatic cancer xenografts, hypoxia experiments, and spatial transcriptomic analyses were used to assess tumor growth and HIF-1α-associated responses.

Results: OPA3 expression varied across cancer types. OPA3 knockout preferentially impaired proliferation and clonogenic growth in the KRAS-mutant cell lines examined, with reduced mitochondrial respiration and ATP production observed in PANC-1 cells. Despite limited effects on KRAS-wild-type BxPC-3 cells in vitro, OPA3 depletion suppressed both PANC-1 and BxPC-3 xenograft growth. Under prolonged hypoxia, OPA3-deficient cells exhibited reduced HIF-1α protein accumulation and impaired clonogenic growth. Spatial transcriptomic analyses identified a positive association between OPA3 and HIF1A expression in pancreatic tumor-associated tissues. However, these observations do not establish direct HIF-1α stabilization or a causal relationship in human tumors.

Conclusions: OPA3 supports pancreatic tumor growth through context-dependent processes associated with mitochondrial metabolism and hypoxic adaptation. Its effects extend beyond KRAS mutation status in xenograft models, although the underlying mechanisms require further validation. These findings identify OPA3 as a candidate regulator of tumor-microenvironment adaptation rather than an established therapeutic target.

References

1. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473. doi:10.1126/science.aaw5473

2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi:10.1158/2159-8290.CD-21-1059

3. Meng N, Glorieux C, Zhang Y, Liang L, Zeng P, Lu W, et al. Oncogenic K-ras induces mitochondrial OPA3 expression to promote energy metabolism in pancreatic cancer cells. Cancers (Basel). 2019;12(1):65. doi:10.3390/cancers12010065

4. Anikster Y, Kleta R, Shaag A, Gahl WA, Elpeleg O. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet. 2001;69(6):1218-1224. doi:10.1086/324651

5. Huizing M, Dorward H, Ly L, Klootwijk E, Kleta R, Skovby F, et al. OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria. Mol Genet Metab. 2010;100(2):149-154. doi:10.1016/j.ymgme.2010.03.005

6. Ryu SW, Jeong HJ, Choi M, Karbowski M, Choi C. Optic atrophy 3 as a protein of the mitochondrial outer membrane induces mitochondrial fragmentation. Cell Mol Life Sci. 2010;67(16):2839-2850. doi:10.1007/s00018-010-0365-z

7. Tsai HW, Li CJ, Lin LT, Chiang AJ, Chen SN, Wen ZH, et al. Expression status and prognostic significance of mitochondrial dynamics OPA3 in human ovarian cancer. Aging (Albany NY). 2022;14(9):3874-3886. doi:10.18632/aging.204050

8. Yang Z, Zhang Y, Wang X, Huang J, Guo W, Wei P, et al. Putative biomarkers of malignant transformation of sinonasal inverted papilloma into squamous cell carcinoma. J Int Med Res. 2019;47(6):2371-2380. doi:10.1177/0300060519838385

9. Yin Y, Ma Z, Yuan S, Xu K, Wang X. OPA3 inhibits the cGAS-STING pathway mediated by mtDNA stress to promote colorectal cancer progression. In Vitro Cell Dev Biol Anim. 2025;61(2):165-177. doi:10.1007/s11626-024-01000-3

10. Wu H, Liu D. OPA3 overexpression modulates lipid droplet production and sensitizes colorectal cancer cells to bevacizumab treatment. Biocell. 2024;48(6):971-980. doi:10.32604/biocell.2024.049466

11. Kang YJ, Pan L, Liu Y, Rong Z, Liu J, Liu F. GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research. Nucleic Acids Res. 2025;53(W1):W283-W290. doi:10.1093/nar/gkaf423

12. Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER 3rd, Kalocsay M, et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell. 2020;180(2):387-402.e16. doi:10.1016/j.cell.2019.12.023

13. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19(1):15. doi:10.1186/s13059-017-1382-0

14. van Dijk D, Sharma R, Nainys J, Yim K, Kathail P, Carr AJ, et al. Recovering gene interactions from single-cell data using data diffusion. Cell. 2018;174(3):716-729.e27. doi:10.1016/j.cell.2018.05.061

15. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2(12):897-909. doi:10.1038/nrc949

16. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337. doi:10.1038/nature11252

17. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-1380. doi:10.1056/NEJMra0802714

18. Suvac A, Ashton J, Bristow RG. Tumour hypoxia in driving genomic instability and tumour evolution. Nat Rev Cancer. 2025;25(3):167-188. doi:10.1038/s41568-024-00781-9

19. Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157. doi:10.1186/s12943-019-1089-9

20. Wang Y, Ying X, Wang Y, Zou Z, Yuan A, Xiao Z, et al. Hydrogen sulfide alleviates mitochondrial damage and ferroptosis by regulating OPA3-NFS1 axis in doxorubicin-induced cardiotoxicity. Cell Signal. 2023;107:110655. doi:10.1016/j.cellsig.2023.110655

21. Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2(12):758-770. doi:10.1016/j.trecan.2016.10.016

22. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408. doi:10.1016/j.cell.2012.01.021

23. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430-439. doi:10.1038/nrc3726

24. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi:10.1038/s41591-018-0014-x

25. Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21(1):208. doi:10.1186/s12943-022-01670-1

26. Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13(12):877-919. doi:10.1007/s13238-021-00846-7

Schematic linking OPA3 with mitochondrial respiration, ATP production, and pancreatic tumor growth and hypoxic adaptation. Purple cells indicate a low-oxygen region within the tumor cluster.

Published

2026-11-14

How to Cite

1.
Qiu Z, Meng N, Ding W, Steponaitienė R, Glorieux C. OPA3 Supports Pancreatic Tumor Growth Through Context-Dependent Metabolic and Hypoxic Adaptation. Cancer Biome Target Ther. [Internet]. 2026 Nov. 14 [cited 2026 Nov. 16];1(4):28-44. Available from: https://cancerbiometherapy.com/index.php/cbtt/article/view/72

Issue

Section

Research Articles

Funding data